Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.56 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28683578 | 0.78 | GHSR (0.47) | QDPRKDM4ELMNAALOX15HSD17B10 | |
| SCHEMBL4162861 | 0.78 | QDPR (0.54) | QDPRHTR1DHTR1BSLC6A4KDM4E | |
| SCHEMBL28421403 | 0.76 | QDPR (0.49) | QDPRHTR1DHTR1BHTR6 | |
| SCHEMBL7501974 | 0.75 | QDPR (0.48) | QDPRHTR1DHTR1BSLC6A4 | |
| SCHEMBL22392118 | 0.74 | JAK1 (0.53) | QDPR | |
| SCHEMBL7369176 | 0.73 | QDPR (0.72) | QDPRSLC6A4 | |
| SCHEMBL23123594 | 0.73 | QDPR (0.52) | QDPRHTR1DHTR1BSLC6A4 | |
| SCHEMBL19107631 | 0.73 | QDPR (0.64) | QDPRHTR1DHTR1BSLC6A4 | |
| SCHEMBL28422171 | 0.72 | QDPR (0.55) | QDPRHTR1DHTR1B | |
| SCHEMBL7499403 | 0.72 | QDPR (0.48) | QDPRHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | claimed |
| EP-1196380-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2002-04-17 | — | — | EP | claimed |
| WO-2001005758-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS ALLELIX CORP. (CA) | 2001-01-25 | — | — | WO | claimed |
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
| EP-1196380-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005758-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS ALLELIX CORP. (CA) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | QDPR 495/4885HTR1D 150/4885HTR1B 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.